


## der(9;18)(p10;q10)

### Identity




+9,der(9; 18)(p10;q10) (G-banding).

### Clinics and Pathology

- Disease** BCR-ABL negative chronic myeloproliferative disorders (CMPD).
- Epidemiology** Occasional occurrence: 5 cases of [polycythemia vera](#) (PV) and one case of therapy associated AML (t-AML) after [ET](#) were reported so far.
- Clinics** 2/5 PV cases showed conversion of PV to post-polycythemic myelofibrosis.
- Prognosis** Probably associated with progression or leukemic transformation of the CMPD.

### Cytogenetics

- Cytogenetics** Unbalanced translocation between chromosomes 9 and 18 leading to trisomy of 9p and monosomy of 18p.
- Morphological**



+9,der(9;18)(p10;q10) (chromosome painting, WCP#9 (red) + WCP#18 (green)).

- Additional anomalies** Sole abnormality in most cases; balanced translocations or complex aberrant karyotypes were reported as additional abnormalities.

### Genes involved and Proteins

Note Genes involved are unknown. Gain of 9p might play a role for gain of function of the [JAK2](#) gene on 9p24 which codes for the JAK2 nonreceptor kinase.

## To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:  
**you are welcome to submit a paper to our new [Case Report](#) section.**

## Bibliography

### Gain of 9p in the pathogenesis of polycythemia vera.

Chen Z, Notohamiprodjo M, Guan XY, Paietta E, Blackwell S, Stout K, Turner A, Richkind K, Trent JM, Lamb A, Sandberg AA.

Genes Chromosomes Cancer. 1998;22:321-324.

Medline [9669670](#)

### Karyotypic abnormalities in myelofibrosis following polycythemia vera.

Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, Bauters F, Lai JL.

Cancer Genet Cytogenet. 2003;140:118-123.

Medline [12645649](#)

### Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.

Bacher U, Haferlach T, Schoch C.

Cancer Genet Cytogenet. 2005;160:179-183.

Medline [15993276](#)

### A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005;352:1779-1790.

Medline [15858187](#)

## Contributor(s)

Written 09-2006 Ulrike Bacher, Claudia Haferlach

## Citation

*This paper should be referenced as such :*

**Bacher U, Haferlach C.** . der(9;18)(p10;q10). Atlas Genet Cytogenet Oncol Haematol. September 2006 .

URL : <http://AtlasGeneticsOncology.org/Anomalies/der918p10q10ID1418.html>

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

---